ASP Isotopes (ASPI) investor relations material

Executive summary

• Revenue for the quarter ended June 30, 2026, was $5.1 million, up from $1.2 million year-over-year, driven by acquisitions and new segment contributions.

• Net loss from continuing operations was $34.0 million for the quarter, a significant improvement from a $75.1 million loss in the prior year period, primarily due to lower fair value adjustments on convertible notes.

• The company completed the acquisition of Renergen, expanding into helium and LNG production, and deconsolidated Skyline, now reported as discontinued operations.

• Three operating segments now include specialist isotopes and related services, nuclear fuels, and helium and LNG.

Financial highlights

• Gross profit for the quarter was $1.5 million, compared to $0.6 million in the prior year.

• Operating expenses rose to $35.7 million from $12.5 million year-over-year, reflecting increased R&D and SG&A costs from acquisitions and expansion.

• Adjusted headline loss per share improved to $(0.25) from $(1.03) year-over-year.

• Cash and cash equivalents at June 30, 2026, were $219.6 million, with short-term investments of $35.3 million.

Outlook and guidance

• Initial commercial shipments of enriched C-14, Si-28, and Yb-176 are targeted for the second half of 2026.

• The company expects existing liquidity to fund operations for more than 12 months but anticipates the need for additional capital for future growth and large-scale projects.

• Phase 2 of the Virginia Gas Project is estimated to require $1.16 billion in capital, with ongoing efforts to secure senior debt funding.